AU8125801A - Method of treating neurodegenerative disorders of the retina and optic nerve head - Google Patents

Method of treating neurodegenerative disorders of the retina and optic nerve head

Info

Publication number
AU8125801A
AU8125801A AU8125801A AU8125801A AU8125801A AU 8125801 A AU8125801 A AU 8125801A AU 8125801 A AU8125801 A AU 8125801A AU 8125801 A AU8125801 A AU 8125801A AU 8125801 A AU8125801 A AU 8125801A
Authority
AU
Australia
Prior art keywords
retina
optic nerve
neurodegenerative disorders
nerve head
treating neurodegenerative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
AU8125801A
Other languages
English (en)
Inventor
Daniel A Gamache
Gustav Graff
John M Yanni
Michael A Kapin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Inc
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of AU8125801A publication Critical patent/AU8125801A/xx
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU8125801A 2000-08-14 2001-08-13 Method of treating neurodegenerative disorders of the retina and optic nerve head Withdrawn AU8125801A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22513200P 2000-08-14 2000-08-14
PCT/US2001/025319 WO2002013805A2 (en) 2000-08-14 2001-08-13 Method of treating neurodegenerative disorders of the retina and optic nerve head

Publications (1)

Publication Number Publication Date
AU8125801A true AU8125801A (en) 2002-02-25

Family

ID=22843666

Family Applications (1)

Application Number Title Priority Date Filing Date
AU8125801A Withdrawn AU8125801A (en) 2000-08-14 2001-08-13 Method of treating neurodegenerative disorders of the retina and optic nerve head

Country Status (16)

Country Link
US (1) US6638976B2 (enExample)
EP (1) EP1309322B1 (enExample)
JP (1) JP2004506010A (enExample)
AR (1) AR030346A1 (enExample)
AT (1) ATE330596T1 (enExample)
AU (1) AU8125801A (enExample)
BR (1) BR0113201A (enExample)
CA (1) CA2418059C (enExample)
CY (1) CY1106155T1 (enExample)
DE (1) DE60120990T2 (enExample)
DK (1) DK1309322T3 (enExample)
ES (1) ES2266229T3 (enExample)
MX (1) MXPA03001160A (enExample)
PT (1) PT1309322E (enExample)
TW (1) TWI286933B (enExample)
WO (1) WO2002013805A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040132773A1 (en) * 2001-08-13 2004-07-08 Gamache Daniel A Method of treating neurodgenerative disorders of the retina and optic nerve head
WO2004112772A1 (en) * 2003-06-13 2004-12-29 Alcon, Inc. Formulations of non-steroidal anti-inflammatory agents to treat pathologic ocular angiogenesis
US20050009910A1 (en) * 2003-07-10 2005-01-13 Allergan, Inc. Delivery of an active drug to the posterior part of the eye via subconjunctival or periocular delivery of a prodrug
TWI358290B (en) * 2004-12-02 2012-02-21 Alcon Inc Topical nepafenac formulations
WO2006121964A2 (en) * 2005-05-10 2006-11-16 Alcon, Inc. Ophthalmic suspension comprising an ophthalmic drug, a poloxamine and a glycol tonicity-adjusting agent, use of said composition for the manufacture of a medicament for treating ophthalmic disorders
PT1885336E (pt) * 2005-05-10 2009-05-07 Alcon Inc Formulações de suspensão compreendendo um princípio activo, um tensoactivo poloxâmero ou meroxapol e um glicol, sua utilização no fabrico de um medicamento para tratamento de distúrbios oftálmicos
US8915877B2 (en) 2010-10-12 2014-12-23 Emmett T. Cunningham, JR. Glaucoma drainage device and uses thereof
US9370444B2 (en) 2010-10-12 2016-06-21 Emmett T. Cunningham, JR. Subconjunctival conformer device and uses thereof
RU2458656C1 (ru) * 2011-06-17 2012-08-20 Федеральное государственное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова Федерального агентства по высокотехнологичной медицинской помощи" Способ лечения оперированного незакрывшегося макулярного отверстия
EP3013790A1 (en) 2013-06-27 2016-05-04 Mylan Laboratories Ltd. Process for the preparation of nepafenac

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1226344A (enExample) 1967-07-31 1971-03-24
SE400966B (sv) 1975-08-13 1978-04-17 Robins Co Inc A H Forfarande for framstellning av 2-amino-3-(eller 5-)bensoyl-fenylettiksyror
US4313949A (en) * 1979-09-26 1982-02-02 A. H. Robins Company, Inc. Method of producing an inhibitory effect on blood platelet aggregation
US4254146A (en) * 1979-10-18 1981-03-03 A. H. Robins Company, Inc. 3-Benzoyl-2-nitrophenylacetic acids, metal salts, amides and esters
IL61945A (en) * 1980-02-19 1984-09-30 Robins Co Inc A H 2-amino-3-(hydroxy(phenyl)methyl)phenylacetic acids,esters and amides and pharmaceutical compositions containing them
DE3026402A1 (de) * 1980-07-11 1982-02-04 Syntex Corp., Palo Alto, Calif. Die verwendung analgetischer und nicht-hormonaler, entzuendungshemmender mittel bei der behandlung von mikrovaskulaeren erkrankungen
US4503073A (en) 1981-01-07 1985-03-05 A. H. Robins Company, Incorporated 2-Amino-3-(alkylthiobenzoyl)-phenylacetic acids
IL64724A0 (en) * 1981-02-17 1982-03-31 Robins Co Inc A H 2-amino-3-(halobenzoyl)-methylphenylacetic acids and esters and salts thereof and pharmaceutical compositions containing them
US4454151A (en) 1982-03-22 1984-06-12 Syntex (U.S.A.) Inc. Use of pyrrolo pyrroles in treatment of ophthalmic diseases
US4568695A (en) * 1983-12-07 1986-02-04 A. H. Robins Company, Incorporated 2-Amino-3-benzoyl-phenethylalcohols and intermediates therefor
EP0195582B1 (en) 1985-03-14 1990-01-24 SMITH KLINE DAUELSBERG GmbH 5-aminosalicylic acid derivatives of non-steroidal antiinflammatory acids
US4851443A (en) 1985-03-14 1989-07-25 Smith Kline Dauelsberg, Gmbh Carboxylic acid amides, compositions and medical use thereof
US4683242A (en) 1985-10-28 1987-07-28 A. H. Robins Company, Incorporated Transdermal treatment for pain and inflammation with 2-amino-3-aroylbenzeneacetic acids, salts and esters
DK406686D0 (da) 1986-08-26 1986-08-26 Hans Bundgaard Carboxylsyrederivater
CA1325382C (en) * 1988-01-27 1993-12-21 Takahiro Ogawa Locally administrable therapeutic composition for inflammatory disease
US5314909A (en) 1993-03-17 1994-05-24 Merck & Co., Inc. Use of non-steroidal antiiflammatory agents in macular degeneration
JP3396953B2 (ja) 1994-05-10 2003-04-14 千寿製薬株式会社 網膜疾患予防・治療剤
US5475034A (en) 1994-06-06 1995-12-12 Alcon Laboratories, Inc. Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders
US5643943A (en) * 1994-12-23 1997-07-01 Alcon Laboratories, Inc. Systemic administration of esters and amides of antioxidants which may be used as antioxidant prodrug therapy for oxidative and inflammatory pathogenesis
US5811446A (en) * 1997-04-18 1998-09-22 Cytos Pharmaceuticals Llc Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor
US6025353A (en) 1997-11-19 2000-02-15 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents
US6066671A (en) 1997-12-19 2000-05-23 Alcon Laboratories, Inc. Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides
EP1148783B1 (en) 1999-01-07 2006-06-07 Vanderbilt University Converting cox inhibition compounds that are not cox-2 selective inhibitors to derivatives that are cox-2 selective inhibitors
US6413965B1 (en) 1999-06-30 2002-07-02 Pfizer Inc. Compositions and treatment for diabetic complications
US6426341B1 (en) 1999-06-30 2002-07-30 Pfizer Inc. Treatment for diabetic complications
US6555540B1 (en) 1999-06-30 2003-04-29 Pfizer Inc Combinations of aldose reductase inhibitors and selective cyclooxygenase-2 inhibitors
US6416777B1 (en) 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device

Also Published As

Publication number Publication date
TWI286933B (en) 2007-09-21
DK1309322T3 (da) 2006-10-23
EP1309322A2 (en) 2003-05-14
CA2418059C (en) 2009-12-22
WO2002013805A3 (en) 2002-05-30
HK1057332A1 (en) 2004-04-02
US6638976B2 (en) 2003-10-28
DE60120990D1 (de) 2006-08-03
BR0113201A (pt) 2006-05-09
US20020049255A1 (en) 2002-04-25
ATE330596T1 (de) 2006-07-15
JP2004506010A (ja) 2004-02-26
ES2266229T3 (es) 2007-03-01
PT1309322E (pt) 2006-11-30
CY1106155T1 (el) 2011-06-08
AR030346A1 (es) 2003-08-20
DE60120990T2 (de) 2007-03-15
CA2418059A1 (en) 2002-02-21
EP1309322B1 (en) 2006-06-21
WO2002013805A2 (en) 2002-02-21
MXPA03001160A (es) 2004-08-02

Similar Documents

Publication Publication Date Title
IL149070A0 (en) Apparatus and method for targeted uv phototherapy of skin disorders
EP1420854A4 (en) TREATMENT OF NEUROPSYCHIATRIC DISORDERS BY NERVE STIMULATION NEAR THE DIAPHRAGM
HUP0400914A3 (en) Methods of treatment of mitochondrial disorders
GR980300033T1 (en) Compositions for the treatment of dermatological disorders and methods for their use
ZA984634B (en) Scleral prosthesis for treatment of presbyopia and other eye disorders
AU2001269799A1 (en) Methods for treating various eye disorders
IL155589A0 (en) Novel amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders
HUP0501017A3 (en) Methods and compositions for treatment of central nervous system disorders
IL146887A0 (en) Improved scleral prosthesis for treatment of presbyopia and other eye disorders
PL368556A1 (en) Methods for treating or preventing skin disorders using cd2-binding agents
GB9908175D0 (en) Method of treating neurological disorders
IL137429A0 (en) Methods and compsitions for treating diseases and conditions of the eye
AU8125801A (en) Method of treating neurodegenerative disorders of the retina and optic nerve head
AU2001271887A1 (en) Methods for diagnosis and treatment of psychiatric disorders
AU5754701A (en) Method of using cox-2 inhibitors in the treatment and prevention of ocular cox-2mediated disorders
AU2001256855A1 (en) Preparation for the prevention and treatment of ocular disorders
HUP0302718A3 (en) Methods and compositions for the treatment of diseases of the eye
AU2002362115A8 (en) Composition and methods for treatment of neurological disorders
IL152782A0 (en) S-methyl-dihydro-ziprasidone for treatment of psychiatric and ocular disorders
AR026062A1 (es) Tratamiento de desordenes oculares
IL131347A0 (en) Treatment of skin disorders
AU2003301346A8 (en) Method of treating neurological diseases and disorders
GB0111441D0 (en) Method and kit for the treatment of cosmetic skin conditions
AU2001236909A1 (en) Method of treating disorders of the eye
PL367097A1 (en) Method of treating dry eye disorders

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired